Phase II study of oxaliplatin plus S-1 as first-line treatment for advanced gastric cancer (G-SOX study). - Wikidata - awgldk - TriplyDB

Phase II study of oxaliplatin plus S-1 as first-line treatment for advanced gastric cancer (G-SOX study).

Phase II study of oxaliplatin plus S-1 as first-line treatment for advanced gastric cancer (G-SOX study).

http://www.wikidata.org/entity/Q33386875

about

Effect of oxaliplatin combined with polyenephosphatidylcholine on the proliferation of human gastric cancer SGC-7901 cells Combination Chemotherapy with S-1 and Oxaliplatin (SOX) as First-Line Treatment in Elderly Patients with Advanced Gastric Cancer.Evaluation of the optimal dosage of S-1 in adjuvant SOX chemotherapy for gastric cancer.Randomised phase II trial of S-1 plus oxaliplatin vs S-1 in patients with gemcitabine-refractory pancreatic cancer.Concurrent Neoadjuvant Chemoradiotherapy for Siewert II and III Adenocarcinoma at Gastroesophageal Junction Can S-1 replace fluorouracil for advanced gastric cancer? A PRISMA-compliant systematic review and meta-analysis Clinical evaluation of cetuximab combined with an S-1 and oxaliplatin regimen for Chinese patients with advanced gastric cancer.Paclitaxel/oxaliplatin/fluorouracil (TOF) regimen versus S-1/oxaliplatin (SOX) regimen for metastatic gastric cancer patients.Thymidylate synthase genotype-directed chemotherapy for patients with gastric and gastroesophageal junction cancers Surgical outcomes in patients with locally advanced gastric cancer treated with S-1 and oxaliplatin as neoadjuvant chemotherapy.S-1-based chemotherapy versus capecitabine-based chemotherapy as first-line treatment for advanced gastric carcinoma: a meta-analysis.Therapeutic effects of combined oxaliplatin and S-1 in older patients with advanced gastric cardiac adenocarcinoma.Combined olaparib and oxaliplatin inhibits tumor proliferation and induces G2/M arrest and γ-H2AX foci formation in colorectal cancer.TPX2 expression is associated with poor survival in gastric cancer.mTOR as a therapeutic target in patients with gastric cancer.Future perspectives for the development of chemotherapy for advanced gastric cancer: Japanese and global status.Optimal chemotherapy for advanced gastric cancer: is there a global consensus?Decreased FANCJ caused by 5FU contributes to the increased sensitivity to oxaliplatin in gastric cancer cells.Results of a randomized and controlled clinical trial evaluating the efficacy and safety of combination therapy with Endostar and S-1 combined with oxaliplatin in advanced gastric cancer.S-1 plus oxaliplatin vs. S-1 as first-line treatment in patients with previously untreated advanced gastric cancer: a randomized phase II study.First-line bolus 5-fluorouracil plus leucovorin for peritoneally disseminated gastric cancer with massive ascites or inadequate oral intake.Phase II trial of preoperative chemoradiation plus perioperative SOX chemotherapy in patients with locally advanced gastric cancer.Treatment using oxaliplatin and S-1 adjuvant chemotherapy for pathological stage III gastric cancer: a multicenter phase II study (TOSA trial) protocol.Immunoclassification characterized by CD8 and PD-L1 expression is associated with the clinical outcome of gastric cancer patients.Hyperthermic intraperitoneal chemotherapy plus simultaneous versus staged cytoreductive surgery for gastric cancer with occult peritoneal metastasis.Paclitaxel combined with oxaliplatin as first-line chemotherapy for locally advanced or metastatic gastric cancer.Phase II study of adjuvant chemotherapy of S-1 plus oxaliplatin for patients with stage III gastric cancer after D2 gastrectomy.Phase I study of neoadjuvant chemotherapy with S-1 and oxaliplatin for locally advanced gastric cancer (Neo G-SOX PI).

P2860

Q28468621-F6CC1CB1-A467-414A-BC53-228869993F5A Q33420157-21574A8D-7830-4B12-8665-9DBFD794FF3F Q33420251-2FB5D5E1-7203-4C68-ADF0-0505FCF3369F Q33422070-739187D2-ADA3-4E84-9F52-93CB7FCFF278 Q33422992-90113B57-B5AD-487A-BB9C-656A8268B04E Q33433129-2541DC4B-994A-4EC4-8B73-1B3A937B4A76 Q33609291-826AD2D1-A609-4058-8EC5-88EE9B085518 Q33728364-A3B24044-C606-4584-AE61-BEBD1CFD3BFE Q34214957-3B270F87-3238-4A04-98AF-CAFD48929451 Q35060024-AD7B25E2-A54C-4AB2-B722-FC4C59DB1B52 Q35070531-E139B9DF-82E0-4C57-9640-320725DF028C Q35627297-B8A1C03A-E20F-44C0-9DC4-5510523E642E Q36211573-735E5382-54DF-476C-8A12-D65DCA3806B0 Q37576195-296A7494-AA69-4C44-9259-DB432E0DD11C Q37928535-064AD6F4-8331-4451-B69E-C4AAEF658E9D Q37959111-DE576E2E-D13A-4588-94C1-7356AE0DEDF6 Q38139297-96C32AFB-9BD0-4727-9A2D-8FE9994AFDF5 Q39280872-E2897336-709D-42C6-B751-3D9A6285DC2D Q43067439-28EA9B94-9D52-4A9B-9CCA-B85AD35ABFA6 Q44064732-C0C27595-8D2E-43FD-8633-DA98EBE9E294 Q48177237-F5B26629-F40D-455D-B8C9-26CFF08CC96C Q48197616-1DEB26D1-2033-4F02-9B6A-EF43ED84E965 Q49554731-01235FDC-3F78-4329-A1D2-4E78A7FA469E Q52649601-E1C81B91-F074-4D3B-B14A-ED1BDB4C89DB Q53546129-082CA1BB-156B-4484-982A-907B3DF40147 Q53560105-1F4131B6-8709-4B93-9692-8917BE6AFD8C Q53652564-97FEEC47-42C0-41A8-BD29-59DD6B3C1A6A Q55005321-5D946F93-D375-4637-8705-BF0DDD729690

P2860

Phase II study of oxaliplatin plus S-1 as first-line treatment for advanced gastric cancer (G-SOX study).

http://www.wikidata.org/entity/Q33386875

description

2009 nî lūn-bûn

@nan

2009 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Phase II study of oxaliplatin ...... gastric cancer (G-SOX study).

@ast

Phase II study of oxaliplatin ...... gastric cancer (G-SOX study).

@en

type

label

Phase II study of oxaliplatin ...... gastric cancer (G-SOX study).

@ast

Phase II study of oxaliplatin ...... gastric cancer (G-SOX study).

@en

prefLabel

Phase II study of oxaliplatin ...... gastric cancer (G-SOX study).

@ast

Phase II study of oxaliplatin ...... gastric cancer (G-SOX study).

@en

P1433

Q33386875-2E728024-A474-4AD8-A083-86A12D2CB374

P1476

Q33386875-379D3C28-7AAB-4357-984A-0E315C78C270

P2093

Q33386875-1233818F-77DB-4356-992E-308AABEC3B49

Q33386875-294AD550-E783-4318-B28F-CEF489662B19

Q33386875-8C5EE006-BA43-4357-8CEC-7C4DD40B27AE

Q33386875-ABA6F416-45E6-4B82-ACB8-E65422E9756A

Q33386875-AD948A3D-B22D-4419-9A39-514140A142EB

Q33386875-D461160D-E77C-47B1-A667-5C96E2FBCC56

Q33386875-D68DE4E9-808B-423E-B013-B241E9FF6F9D

Q33386875-E7A854B2-D484-43C4-992F-4A5BE5A75844

P2860

Q33386875-227DC97A-63C5-4104-BC86-9504E510DE62

Q33386875-22DD6681-6BF6-429B-A7B7-FF4E772DD970

Q33386875-5FE84236-52EA-4C99-8280-C41FCC1935FD

Q33386875-63FF310C-95DB-4A2E-BFE8-207117BD882C

Q33386875-6DFC459D-66EF-4441-A0C0-6FB095B52907

Q33386875-6EEA8BCC-470A-4B9F-9CF7-BD283AB2061E

Q33386875-72E58E20-4E4E-4442-AD6F-BE829D2F1C20

Q33386875-8C0913BD-C695-49E6-A776-63BD1ACAFE08

Q33386875-DD5D7108-0DAC-41AC-BF33-50F134AA4F33

Q33386875-E67830A2-07D7-4501-B1E8-38DF3D80783C

P304

Q33386875-7D2884F4-6F80-424C-B891-FAC3BEE79B4F

P31

Q33386875-CD7C50B7-CB45-474E-94BE-DD620546F8AD

P356

Q33386875-3EE15721-519E-4526-98E8-52B8AF91833C

P433

Q33386875-F89D0F5E-8084-407A-8A9E-5327060DFA6C

P478

Q33386875-F3DD459D-5250-4E63-887F-B67CFAAA544B

P577

Q33386875-EAD26A65-4939-4210-A1DC-0F25569486BA

P5875

Q33386875-E4A35325-B443-4963-BC15-BBA85E61B5AF

P698

Q33386875-A9490DD0-16F3-402A-B4E5-9C27CB840F53

P356

P1433

Annals of Oncology

P1476

Phase II study of oxaliplatin ...... gastric cancer (G-SOX study).

@en

P2093

A Tsuburaya

http://www.w3.org/2001/XMLSchema#string

H Takiuchi

http://www.w3.org/2001/XMLSchema#string

K Muro

http://www.w3.org/2001/XMLSchema#string

N Boku

http://www.w3.org/2001/XMLSchema#string

N Fuse

http://www.w3.org/2001/XMLSchema#string

W Koizumi

http://www.w3.org/2001/XMLSchema#string

Y Komatsu

http://www.w3.org/2001/XMLSchema#string

Y Yamada

http://www.w3.org/2001/XMLSchema#string

P2860

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

Capecitabine and oxaliplatin for advanced esophagogastric cancer.

Phase I/II study of oxaliplatin with oral S-1 as first-line therapy for patients with metastatic colorectal cancer.

Phase II study with oxaliplatin and S-1 for patients with metastatic colorectal cancer.

Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer.

Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer.

Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group.

S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial.

Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial.

Long-term survival after epirubicin, cisplatin and fluorouracil for gastric cancer: results of a randomized trial.

P304

1001-1005

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/ANNONC/MDP464

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

21

http://www.w3.org/2001/XMLSchema#string

P577

2009-10-29T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

38054222

http://www.w3.org/2001/XMLSchema#string

P698

19875759

http://www.w3.org/2001/XMLSchema#string